MedTrace Logo

Utility of MicroRNAs for Diagnosing Hepatocellular Carcinoma in Hepatitis C Patients

NCT07404566 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2026-02-12

No results posted yet for this study

Summary

This study evaluates a target population of patients with Hepatitis C virus (HCV) infection, including those with complications like liver cirrhosis (LC) and hepatocellular carcinoma (HCC), to investigate the diagnostic utility of a specific panel of microRNAs (miRNAs). The intervention involves quantifying the plasma expression (PE) levels of MiR-21, 1246, 205, 29a-3p, and 497 via PCR and comparing them to healthy controls to determine their efficacy as biomarkers. The primary outcome is to assess the sensitivity, specificity, and overall accuracy of these miRNAs in differentiating HCC from cirrhotic and non-cirrhotic HCV cases, aiming to establish more reliable screening tools than current standard biomarkers like alpha-fetoprotein (AFP).

Conditions

Interventions

DIAGNOSTIC_TEST

PCR

PCR quantification of plasma microRNA levels (MiR-21, 1246, 205, 29a-3p, and 497).

Sponsors & Collaborators

  • Benha University

    lead OTHER

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-15
Primary Completion
2025-11-25
Completion
2025-12-25

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07404566 on ClinicalTrials.gov